Oncology development

FDA Declines Optune Mya After the Phase 3 METIS Trial Met Its Primary Endpoint

Review the Optune Mya FDA decision, what the Phase 3 METIS brain metastases trial measured, and how trial teams can protect follow-up after treatment stops.

By Lampgen Clinical Research

A research coordinator sets down a folder beside an illustrative brain MRI. The cover asks, “When treatment stops, who owns follow-up?”
Editorial illustration of a clinical research handoff and a simulated MRI.
15.0 months with Tumor Treating Fields7.5 months in the control group
Median time to progression in the brain after stereotactic radiosurgery in Phase 3 METIS. Both groups received supportive care. [2, 3]

What the source reported

On November 9, 2026, Novocure reported receiving a Not Approvable Letter from the U.S. Food and Drug Administration for Optune Mya. The proposed use was after stereotactic radiation in adults with brain metastases from non-small cell lung cancer. According to Novocure’s SEC-filed disclosure, uncertainty about the extent of clinical benefit prevented approval. The decision comes after the randomized Phase 3 METIS trial met its primary endpoint for delaying progression in the brain. [1–3]

What the METIS trial measured

METIS randomized 298 adults with one to ten newly diagnosed brain metastases suitable for stereotactic radiosurgery. Both groups received radiosurgery and supportive care alongside treatment for cancer outside the brain. The intervention group also received Tumor Treating Fields, low-intensity alternating electric fields delivered through arrays worn on the scalp. An independent radiology committee assessed progression in the brain. [2, 4]

At a median follow-up of 8.6 months, the final analysis reported a median of 15.0 months to intracranial progression with Tumor Treating Fields and 7.5 months in the control group. The hazard ratio was 0.72 (95% confidence interval 0.53–0.98, p = 0.044 in a competing-risk analysis). Overall survival and time to neurocognitive failure showed statistically inconclusive differences. Exploratory analyses favored the device on some quality-of-life measures, including physical functioning and fatigue. Most device-related adverse events were mild or moderate skin reactions. [2, 3]

What would more time before progression mean for patients?

A longer interval before progression in the brain could be valuable to a patient hoping to stay independent or defer another brain-directed treatment. Those benefits call for their own measurements. The treatment schedule matters, too. The study aimed for at least 18 hours of device use each day, and investigators reported median monthly use of 67.1% of available time. Both the potential benefit and the demands of treatment belong in the same discussion. [2, 4, 5]

Novocure plans to meet with the FDA to discuss whether there is a path to approval using the existing evidence. That discussion will help clarify whether further analyses or additional clinical data are needed. [1]

What this means for trial teams

Plan the assessment before the first participant enrolls. Choose a small set of outcomes patients and caregivers can recognize, such as the ability to manage daily tasks or time until another brain-directed intervention. Define the assessment method, the timing in relation to MRI, and how the analysis will handle events such as death or a new treatment. At site startup, check that visits and assessments are practical for people traveling to a specialist center. [6]

Give post-treatment follow-up a named owner. When a participant stops using an investigational device and agrees to remain in follow-up, the site should know who schedules protocol-required imaging, who completes cognitive or quality-of-life assessments, and where each result goes. During monitoring, confirm that a missed assessment has a documented reason. A transportation barrier, a hospitalization, and a participant’s decision to decline further assessments each require a different response. Follow the protocol and the scope of the participant’s consent. [7]

Look for patterns while there is time to act. Review completion and documented reasons by site and assessment window, including whether participants remain on treatment. With Lampgen’s SIGNAL™ framework, investigate a repeat gap, check whether it appears elsewhere, and give the appropriate team an action and a due date. If the fix is a revised site handoff, check the next follow-up window to see whether the expected assessments reached the study record. [8]

Sources

  1. Novocure, SEC Form 8-K exhibit on the Optune Mya regulatory decision, November 9, 2026
  2. Mehta et al., final Phase 3 METIS results, International Journal of Radiation Oncology, Biology, Physics
  3. Novocure, final METIS results and median times to intracranial progression
  4. ClinicalTrials.gov, Phase 3 METIS study record NCT02831959
  5. Gondi et al., final METIS results presented at ASTRO 2025
  6. Lampgen Clinical Insights, patient-reported outcomes in oncology trials
  7. FDA, ICH E6(R3) Good Clinical Practice guidance
  8. Lampgen, a worked SIGNAL™ monitoring case

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?